Comparing Cadrenal Therapeutics (CVKD) & Its Rivals

Cadrenal Therapeutics (NASDAQ:CVKD) is one of 952 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Cadrenal Therapeutics to similar businesses based on the strength of its dividends, risk, valuation, institutional ownership, profitability, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of current ratings for Cadrenal Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	0	0	2	0	3.00
Cadrenal Therapeutics Competitors	6244	18207	42955	875	2.56

Cadrenal Therapeutics currently has a consensus price target of $3.50, suggesting a potential upside of 729.97%. As a group, “Pharmaceutical preparations” companies have a potential upside of 80.71%. Given Cadrenal Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Cadrenal Therapeutics is more favorable than its peers.

Institutional & Insider Ownership

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 44.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 58.1% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Cadrenal Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	-$8.36 million	-0.61
Cadrenal Therapeutics Competitors	$1.96 billion	$98.43 million	-4.64

Cadrenal Therapeutics’ peers have higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Cadrenal Therapeutics has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics’ peers have a beta of 0.79, suggesting that their average stock price is 21% less volatile than the S&P 500.

Profitability

This table compares Cadrenal Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-128.67%	-117.76%
Cadrenal Therapeutics Competitors	-2,646.05%	-227.44%	-30.04%

Summary

Cadrenal Therapeutics beats its peers on 8 of the 13 factors compared.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.